A preclinical study reported that sustained exosome delivery improved bone formation in p75NTR-deficient mice, supporting the idea that longer-term exosome exposure may overcome deficits seen in genetic bone phenotypes. Researchers used a sustained-release nanofibrous membrane to deliver wild-type stem-cell extracellular vesicles. The approach was tested in both bone-cell contexts and a cranial defect model, where treated animals showed improved bone regeneration compared with controls. While the data strengthen the rationale for exosome-based regenerative programs, the study remains preclinical and does not establish safety or efficacy in humans. For translational programs, the delivery platform is often the bottleneck for extracellular vesicle therapeutics—so a membrane-based sustained release strategy is notable because it aims to maintain local exposure rather than relying on short-lived vesicle retention. The finding aligns with a wider emphasis on engineering dosing schedules and local microenvironments for cell-free biologics, especially in indications where scaffold persistence and growth-factor-like signaling duration may be critical.